Your session is about to expire
← Back to Search
tRAS Brain Stimulation for Executive Dysfunction (TRAS Trial)
N/A
Recruiting
Led By Justin Riddle, PhD
Research Sponsored by Florida State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Normal or corrected-to-normal vision
Between the ages of 18 and 35
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 hours
Awards & highlights
TRAS Trial Summary
This trial investigates how different types of brain signals (low-frequency oscillations and aperiodic signals) are related to working memory capacity.
Who is the study for?
This trial is for individuals aged 18-35 with normal or corrected-to-normal vision, who can understand English without a translator and are not color-blind. Participants must be able to consent to the study and commit to its duration.Check my eligibility
What is being tested?
The study examines how different types of transcranial alternating current stimulation (tRAS) affect working memory. It compares Sham-tRAS (a placebo), Flat-tRAS, and Steep-tRAS on their ability to influence cognitive function.See study design
What are the potential side effects?
While the document doesn't specify side effects, tRAS may cause mild discomfort, itching or tingling at the electrode sites, headache, fatigue or nausea during or after treatment.
TRAS Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My vision is normal or corrected to normal.
Select...
I am between 18 and 35 years old.
TRAS Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in number of remembered items
Secondary outcome measures
Change in slope of the power spectrum of the EEG
TRAS Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Steep-tRAS,Experimental Treatment1 Intervention
Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. The condition of interest, steep-tRAS, mimics a steep slope of the aperiodic signal characterized by greater low relative to high frequency power. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
Group II: Flat-tRASActive Control1 Intervention
Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. The active control, flat-tRAS, mimics a flat slope aperiodic signal characterized by greater high relative to low frequency power. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
Group III: Sham-tRASPlacebo Group1 Intervention
Transcranial random aperiodic stimulation (tRAS) delivers 1 milliampere (mA) zero-to-peak amplitude at the target electrodes and 2 mA at the return electrode. For active sham stimulation, steep-tRAS or flat-tRAS is delivered for only 15 seconds at the beginning and end of the block. This mimics the skin sensations (e.g., itching, burning, tingling) to assist with blinding the participant. Participants receive all three types of stimulation in an intermixed, balanced, and randomized order. There are twelve total blocks of approximately five minutes of stimulation with four blocks of each type of stimulation.
Find a Location
Who is running the clinical trial?
Florida State UniversityLead Sponsor
200 Previous Clinical Trials
31,728 Total Patients Enrolled
Justin Riddle, PhDPrincipal InvestigatorFlorida State University
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is this study open to individuals who are younger than 55 years old?
"This study is specifically targeting individuals aged 18 to 35. There are an additional 12 trials that accommodate minors while 11 focus on patients over the age of 65."
Answered by AI
Do I meet the criteria to participate in this research?
"To be included in this medical study, potential participants must demonstrate executive dysfunction and are required to fall within the ages of 18-35 years old. The total enrollment sought is 30 persons."
Answered by AI
Is availability open for this trial to enroll participants?
"According to clinicaltrials.gov, this particular research does not have an open call for participants at present. The trial was initially posted on January 1st 2024 and the last information update happened November 9th 2023. However, 24 other trials are presently seeking volunteers."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger